Dendritic cell hybrid nanovaccine for mild heat inspired cancer immunotherapy

J Nanobiotechnology. 2023 Sep 26;21(1):347. doi: 10.1186/s12951-023-02106-8.

Abstract

Cancer therapeutic vaccine can induce antigen-specific immune response, which has shown great potential in cancer immunotherapy. As the key factor of vaccine, antigen plays a central role in eliciting antitumor immunity. However, the insufficient antigen delivery and low efficiency of antigen presentation by dendritic cells (DCs) have greatly restricted the therapeutic efficiency of vaccine. Here we developed a kind of DC hybrid zinc phosphate nanoparticles to co-deliver antigenic peptide and photosensitive melanin. Owing to the chelating ability of Zn2+, the nanoparticles can co-encapsulate antigenic peptide and melanin with high efficiency. The nanovaccine showed good physiological stability with the hydration particle size was approximately 30 nm, and zeta potential was around - 10 mV. The nanovaccine showed homologous targeting effect to DCs in vivo and in vitro, efficiently delivering antigen to DCs. Meanwhile, the nanovaccine could effectively reflux to the tumor-draining lymph nodes. When combined with near-infrared irradiation, the nanovaccine induced effective mild heat in vitro and in vivo to promote antigen presentation. After administrating to MC38 tumor-bearing mice, the hybrid nanovaccine effectively promoted the maturation of DCs, the expansion of cytotoxic T lymphocytes and helper T cells, and the secretion of immunostimulatory cytokines, thereby significantly inhibiting tumor growth.

Keywords: Cell membrane; Dendritic cell; Immunotherapy; Mild heat; Nanovaccine.

MeSH terms

  • Animals
  • Cancer Vaccines*
  • Dendritic Cells
  • Hot Temperature
  • Immunization
  • Immunotherapy
  • Melanins
  • Mice
  • Neoplasms* / therapy

Substances

  • Melanins
  • Cancer Vaccines